--- title: "Cannabis Bioscience International Holdings, Inc. | 10-Q: FY2026 Q3 Revenue: USD 11.21 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/283045980.md" datetime: "2026-04-16T19:41:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283045980.md) - [en](https://longbridge.com/en/news/283045980.md) - [zh-HK](https://longbridge.com/zh-HK/news/283045980.md) --- # Cannabis Bioscience International Holdings, Inc. | 10-Q: FY2026 Q3 Revenue: USD 11.21 K Revenue: As of FY2026 Q3, the actual value is USD 11.21 K. EPS: As of FY2026 Q3, the actual value is USD 0. EBIT: As of FY2026 Q3, the actual value is USD -82.48 K. #### Segment Revenue **Three Months Ended February 28:** Total revenues were $11,205 in 2026, a decrease from $14,931 in 2025, primarily due to a reduction in clinical trial contracts . Clinical trials revenue was $11,200 in 2026, down from $14,931 in 2025 . Merchandise revenue increased to $5 in 2026 from $0 in 2025 . Consulting fees and Seminar fees remained $0 for both periods . **Nine Months Ended February 28:** Total revenues were $88,671 in 2026, a significant decrease from $268,066 in 2025 . Clinical trials revenue was $76,242 in 2026, compared to $267,098 in 2025 . Consulting fees generated $12,000 in 2026, up from $0 in 2025 . Seminar fees were $291 in 2026, compared to $0 in 2025 . Merchandise revenue was $138 in 2026, down from $968 in 2025 . #### Operational Metrics **Three Months Ended February 28:** Cost of revenues decreased to $3,045 in 2026 from $19,396 in 2025 . Gross profit was $8,160 in 2026, an improvement from - $4,465 in 2025 . Total operating expenses decreased to $101,419 in 2026 from $124,769 in 2025 . General and administrative expenses decreased by $23,344 to $26,828 in 2026 from $50,172 in 2025 . Contract labor decreased to $37,865 in 2026 from $45,382 in 2025 . Professional fees increased to $13,185 in 2026 from $9,730 in 2025 . Officer compensation increased to $11,089 in 2026 from $6,000 in 2025 . Operating loss decreased to - $93,259 in 2026 from - $129,234 in 2025 . Net loss for the quarter was - $103,933 in 2026, compared to - $181,243 in 2025 . **Nine Months Ended February 28:** Cost of revenues decreased to $21,688 in 2026 from $35,561 in 2025 . Gross profit was $66,983 in 2026, a decrease from $232,505 in 2025 . Total operating expenses were $330,903 in 2026, down from $518,970 in 2025 . Operating loss was - $263,920 in 2026, an improvement from - $286,465 in 2025 . Net loss for the nine months was - $303,546 in 2026, compared to - $337,076 in 2025 . #### Cash Flow **Nine Months Ended February 28:** Net cash used in operations was - $123,802 in 2026, an improvement from - $185,315 in 2025 . Net cash provided by financing activities was $110,940 in 2026, down from $185,108 in 2025 . Cash at the end of the period was $90 in 2026, significantly lower than $548 in 2025 . #### Key Financial Condition Indicators - As of February 28, 2026, Cannabis Bioscience International Holdings, Inc. had $90 in cash and cash equivalents and accounts receivable of $1,266 . - The company reported negative working capital of - $1,217,630 at February 28, 2026, compared to - $916,878 at May 31, 2025 . - The accumulated deficit was - $6,186,448 at February 28, 2026, compared to - $5,882,901 at May 31, 2025 . #### Future Outlook and Strategy Cannabis Bioscience International Holdings, Inc.’s ability to continue as a going concern depends on the successful execution of its operating plan, which includes increasing sales of existing services and introducing new services . The company also needs to raise additional debt or equity financing to fund its business and repay its debts . There is no assurance that such capital can be obtained, and failure to do so could materially negatively impact operations or force termination . ### Related Stocks - [CBIH.US](https://longbridge.com/en/quote/CBIH.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)